Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic–epigenetic interactions
Medical Oncology · 23.06.2026 · 43 (7)
DOI: 10.1007/s12032-026-03323-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 23.06.2026. Verfasst von Chen Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Epigenesis, Genetic, Lactic Acid. Die Arbeit nennt 98 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the "13th Five-Year Plan" Science and Education Strong Health Project Innovation Team of Yangzhou, the Provincial-Level Discipline Leader of the NJPH.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy with persistently high and increasing mortality rates. Once regarded merely as a metabolic byproduct, lactate is now recognized as a key metabolite in the tumor microenvironment (TME), where it promotes HCC progression through diverse biological functions. Lactylation, a unique post-translational modification, regulates the TME by altering gene expression via the addition of lactate-derived groups to both histone and non-histone proteins. This review summarizes the role of lactate metabolism in the body, examines its effects on various immune cell populations, and highlights recent advances in anti-HCC therapies targeting lactate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
- Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital, Yangzhou, China.
- Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China. drbaidousheng@yzu.edu.cn.
- Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital, Yangzhou, China. drbaidousheng@yzu.edu.cn.
ORCID-Profile: Dousheng Bai
Förderung
- the National Natural Science Foundation of China
- the "13th Five-Year Plan" Science and Education Strong Health Project Innovation Team of Yangzhou
- the Provincial-Level Discipline Leader of the NJPH
- the Cross-Cooperation Special Projects of the NJPH
- the Beiing iGanDan Foundation
- Yangzhou Basic Research Program (Joint Special Project)
- Health research major project in Jiangsu Province
- the Postgraduate Research and Practice Innovation Program of Jiangsu Province
Zitieren
APA
Chen, C., Miao, Y., Fan, S., Tang, C., Peng, R., Zhang, J., Cao, J., Zhang, C., & Bai, D. (2026). Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic–epigenetic interactions. Medical Oncology, 43(7). https://doi.org/10.1007/s12032-026-03323-5
Vancouver
Chen C, Miao Y, Fan S, Tang C, Peng R, Zhang J, et al. Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic–epigenetic interactions. Medical Oncology. 2026;43(7). doi:10.1007/s12032-026-03323-5
BibTeX
@article{Chen2026,
author = {Chen, Chen and Miao, Yangyang and Fan, Songsong and Tang, Chengji and Peng, Rui and Zhang, Jiahao and Cao, Jun and Zhang, Chi and Bai, Dousheng},
title = {Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic–epigenetic interactions},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {7},
doi = {10.1007/s12032-026-03323-5}
}
EUVIMED